Leslie Wetzel

1.0k total citations
11 papers, 661 citations indexed

About

Leslie Wetzel is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Leslie Wetzel has authored 11 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Leslie Wetzel's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and HER2/EGFR in Cancer Research (3 papers). Leslie Wetzel is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and HER2/EGFR in Cancer Research (3 papers). Leslie Wetzel collaborates with scholars based in United States, Japan and Netherlands. Leslie Wetzel's co-authors include Jonathan Rios‐Doria, Robert E. Hollingsworth, Raymond Rothstein, Jon Chesebrough, Binyam Bezabeh, Nazzareno Dimasi, Ryan Fleming, Wei Zhao, Ching Ching Leow and Nicholas Holoweckyj and has published in prestigious journals such as Cancer Cell, Cancer Research and Journal of Controlled Release.

In The Last Decade

Leslie Wetzel

10 papers receiving 637 citations

Peers

Leslie Wetzel

ONCOL

RNMI

IMMUN

Elena Luison Italy

Kelly Davis Orcutt United States

Katharine C. Lai United States

Shundong Ji China

Stijn J.H. Waaijer Netherlands

Tal Flieswasser Belgium

Xuesai Zhang China

Fanny Bouquet France

Mike Zhong China

J. Gutheil United States

Elena Luison Italy

Leslie Wetzel

166 ×0.4

ONCOL

224 ×0.8

RNMI

246 ×1.3

107 ×0.6

IMMUN

33 ×0.3

Citations per year, relative to Leslie Wetzel Leslie Wetzel (= 1×) peers Elena Luison

Countries citing papers authored by Leslie Wetzel

Since Specialization

Citations

This map shows the geographic impact of Leslie Wetzel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leslie Wetzel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leslie Wetzel more than expected).

Fields of papers citing papers by Leslie Wetzel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leslie Wetzel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leslie Wetzel. The network helps show where Leslie Wetzel may publish in the future.

Co-authorship network of co-authors of Leslie Wetzel

This figure shows the co-authorship network connecting the top 25 collaborators of Leslie Wetzel. A scholar is included among the top collaborators of Leslie Wetzel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leslie Wetzel. Leslie Wetzel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Tu, Eric, Kelly McGlinchey, Jixin Wang, et al.. (2022). Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight. 7(3). 75 indexed citations

Tu, Eric, Kelly McGlinchey, Susan Wilson, et al.. (2020). Abstract 911: Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR mutant NSCLC. Cancer Research. 80(16_Supplement). 911–911. 1 indexed citations

Tyagi, Puneet, Sergei Pechenov, Jonathan Rios‐Doria, et al.. (2018). Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach. Journal of Pharmaceutical Sciences. 108(4). 1590–1597. 2 indexed citations

Rios‐Doria, Jonathan, Jay Harper, Raymond Rothstein, et al.. (2017). Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Research. 77(10). 2686–2698. 91 indexed citations

Rios‐Doria, Jonathan, Jay Harper, Raymond Rothstein, et al.. (2017). Abstract 4596: Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads alter the tumor immune microenvironment and synergize with multiple immunotherapies. Cancer Research. 77(13_Supplement). 4596–4596. 1 indexed citations

Xiao, Zhan, Rosa A. Carrasco, Kevin Schifferli, et al.. (2016). A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response. Molecular Cancer Therapeutics. 15(4). 689–701. 27 indexed citations

Gilbreth, Ryan, Leslie Wetzel, Horacio Cabral, et al.. (2016). Lipid- and polyion complex-based micelles as agonist platforms for TNFR superfamily receptors. Journal of Controlled Release. 234. 104–114. 15 indexed citations

Perry, Samuel R., Vanessa Muniz‐Medina, Xinzhong Wang, et al.. (2016). A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell. 29(1). 117–129. 292 indexed citations

Li, John, Dorin Toader, Samuel R. Perry, et al.. (2016). Abstract 2970: MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in vitro and in vivo activity in preclinical studies. Cancer Research. 76(14_Supplement). 2970–2970. 6 indexed citations

10.

Rios‐Doria, Jonathan, Nicholas M. Durham, Leslie Wetzel, et al.. (2015). Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia. 17(8). 661–670. 146 indexed citations

11.

Kamal, Adeela, Youzhen Wang, Philipp Steiner, et al.. (2013). Abstract 5462: MEDI3185, a potent anti-CXCR4 antibody, inhibits tumor cell migration, signaling and tumor growth in preclinical models.. Cancer Research. 73(8_Supplement). 5462–5462. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact